Loading
Niraparib maintenance after first-line chemotherapy delayed progression in newly diagnosed advanced ovarian cancer whether or not the tumour had a homologous recombination deficiency, though the gain was much larger when it did.
Phase 3 placebo-controlled trial of 733 patients with newly diagnosed advanced high-grade ovarian cancer at high risk of relapse who had responded to platinum chemotherapy, randomised to niraparib or placebo maintenance.
In homologous recombination-deficient tumours median progression-free survival was 21.9 versus 10.4 months (hazard ratio 0.43); in the overall population it was 13.8 versus 8.2 months (hazard ratio 0.62), with a smaller benefit in homologous recombination-proficient disease (hazard ratio 0.68).
Niraparib is approved as first-line maintenance for all comers, making PARP inhibitor maintenance available beyond BRCA-mutated disease, though the benefit in proficient tumours is modest and long-term survival data are neutral.
Shares ctDNA-guided duration of PARP maintenance, New England Journal of Medicine.
Shares ctDNA-guided duration of PARP maintenance, High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer.
Shares Platinum-sensitive ovarian cancer, New England Journal of Medicine.
Shares ctDNA-guided duration of PARP maintenance, High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer, New England Journal of Medicine.
Shares High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer.
Shares High-grade serous ovarian cancer, New England Journal of Medicine.
Shares High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer, Niraparib.